BioCentury
ARTICLE | Clinical News

Arhalofenate: Completed Phase IIb enrollment

October 6, 2014 7:00 AM UTC

CymaBay completed enrollment of >225 patients in a double-blind, placebo-controlled, international Phase IIb trial comparing 600 and 800 mg oral arhalofenate once daily vs. 300 mg oral allopurinol onc...